Powder: -20°C for 3 years | In solvent: -80°C for 1 year
hBChE-IN-1 (compound 4), a quinolizidinyl derivative, effectively inhibits human Butyrylcholinesterase (hBChE) with an IC50 value of 7 nM, demonstrating high selectivity against human Acetylcholinesterase (hAChE). It also possesses inhibitory properties against tau and Aβ 40 protein aggregation, exhibiting IC50 values of 20 and 4.3 μM, respectively, making it a valuable asset for Alzheimer's disease research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | hBChE-IN-1 (compound 4), a quinolizidinyl derivative, effectively inhibits human Butyrylcholinesterase (hBChE) with an IC50 value of 7 nM, demonstrating high selectivity against human Acetylcholinesterase (hAChE). It also possesses inhibitory properties against tau and Aβ 40 protein aggregation, exhibiting IC50 values of 20 and 4.3 μM, respectively, making it a valuable asset for Alzheimer's disease research [1]. |
Molecular Weight | 466.7 |
Formula | C27H34N2OS2 |
CAS No. | 1776948-12-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
hBChE-IN-1 1776948-12-9 inhibitor inhibit